You are in: eMedicine Specialties > Dermatology > BACTERIAL INFECTIONS EcthymaArticle Last Updated: Feb 28, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Loretta Davis, MD, Professor, Department of Internal Medicine, Division of Dermatology, Medical College of Georgia Loretta Davis is a member of the following medical societies: American Academy of Dermatology Coauthor(s): Carmen Mays, MD, Fellow, Department of Anesthesiology, University of Michigan Hospitals Editors: Donald Belsito, MD, Clinical Professor, Department of Internal Medicine, Division of Dermatology, University of Missouri at Kansas City; Private Practice, American Dermatology Associates, LLC; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Lester F Libow, MD, Dermatopathologist, South Texas Dermatopathology Laboratory; Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System Author and Editor Disclosure Synonyms and related keywords: ulcerative pyoderma, cutaneous pyoderma, impetigo, deep impetigo, pyodermic lesion, skin streptococci, group A beta-hemolytic streptococci, group A beta-hemolytic Streptococcus, GABHS, ecthymatous ulcer, ecthymatous ulceration, group A streptococci, GAS, group A Streptococcus INTRODUCTIONBackgroundEcthyma is an ulcerative pyoderma of the skin caused by group A beta-hemolytic streptococci. Because ecthyma extends into the dermis, it is often referred to as a deeper form of impetigo. See Impetigo for more information. PathophysiologyEcthyma begins similarly to superficial impetigo. Group A beta-hemolytic streptococci may initiate the lesion or may secondarily infect preexisting wounds. Preexisting tissue damage (eg, excoriations, insect bites, dermatitis) and immunocompromised states (eg, diabetes, neutropenia) predispose patients to the development of ecthyma. Spread of skin streptococci is augmented by crowding and poor hygiene. FrequencyInternationalThe exact incidence worldwide remains unknown. Mortality/MorbidityEcthyma rarely leads to systemic symptoms or bacteremia. Lesions are painful and can have associated lymphadenopathy. Secondary lymphangitis and cellulitis can occur. Ecthyma does heal with scarring. The rate of poststreptococcal glomerulonephritis is approximately 1%. RaceNo racial predisposition is recognized. SexNo sexual predisposition is recognized. AgeEcthyma has a predilection for children and elderly individuals. CLINICALHistory
Physical
Causes
DIFFERENTIALSEcthyma Gangrenosum Insect Bites Leishmaniasis Lymphomatoid Papulosis Mycobacterium Marinum Infection of the Skin Papulonecrotic Tuberculids Pyoderma Gangrenosum Sporotrichosis Tungiasis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Penicillin G benzathine (Bicillin LA) |
|---|---|
| Description | DOC when a pyoderma is known to be caused by group A streptococci. Interferes with synthesis of cell wall mucopeptides during active multiplication, which results in bactericidal activity. |
| Adult Dose | 600,000-1.2 million U IM |
| Pediatric Dose | <60 lb: 600,000 U IM >60 lb: 1.2 million U IM |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid can increase effectiveness by decreasing clearance; coadministration with tetracyclines can decrease effectiveness |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in impaired renal function; avoid intravascular injection |
| Drug Name | Penicillin VK (Veetids, Beepen-VK) |
|---|---|
| Description | Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. |
| Adult Dose | 0.25-0.5 g PO qid |
| Pediatric Dose | 25-50 mg/kg/d divided q6-8h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid can increase effects by decreasing clearance; coadministration of tetracyclines can decrease effects |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in impaired renal function |
| Drug Name | Erythromycin (E.E.S., E-Mycin, Ery-Tab) |
|---|---|
| Description | Suitable alternative for patients who are allergic to penicillin. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily dose may be taken q12h. For more severe infections, double the dose. |
| Adult Dose | 250-500 mg PO qid |
| Pediatric Dose | 30-50 mg/kg/d PO divided q8-12h |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis; coadministration of strong CYP3A inhibitors (eg, diltiazem, verapamil, nitroimidazole antifungal agents) increases risk of sudden death from ventricular arrhythmias |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; adverse GI effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
| Drug Name | Cephalexin (Keflex, Biocef) |
|---|---|
| Description | First-generation cephalosporin arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora; used for skin infections or prophylaxis in minor procedures. Active against Streptococcus pyogenes and S aureus. |
| Adult Dose | 250-500 mg PO qid |
| Pediatric Dose | 25-50 mg/kg/d PO divided qid |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aminoglycosides increases nephrotoxic potential |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Patients with a history of IgE-mediated allergic reactions to penicillin may have similar reactions to cephalosporins; adjust dose in renal impairment |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. |
| Adult Dose | 150-300 mg PO qid |
| Pediatric Dose | 10-20 mg/kg/d PO divided tid/qid |
| Contraindications | Documented hypersensitivity; regional enteritis, ulcerative colitis, hepatic impairment, antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
| Drug Name | Dicloxacillin (Dycill, Dynapen) |
|---|---|
| Description | Treatment of infections caused by penicillinase-producing staphylococci. May use to initiate therapy when staphylococcal infection is suggested. |
| Adult Dose | 125-500 mg PO qid |
| Pediatric Dose | 12.5-50 mg/kg/d PO divided into 4-6 doses |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effect of penicillins; tetracyclines may decrease effect of penicillins with concurrent use |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in impaired renal function |
| Drug Name | Mupirocin (Bactroban) |
|---|---|
| Description | Selectively binds to bacterial isoleucyl transfer-RNA synthetase, inhibiting protein synthesis. |
| Adult Dose | Apply thin film to affected area bid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Prolonged use may result in growth of nonsusceptible organisms; local reactions have been reported (ie, burning, pain, pruritus, erythema, dry skin, tenderness, cellulitis) |
| Media file 1: Typical ecthyma lesions of the lower extremities. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: The stages of ecthyma. The lesion begins as a pustule that later erodes and ultimately forms an ulcer. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Feb 28, 2007